Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Blinded, Parallel-Group, Phase 2 Study Exploring the Safety, Tolerability, and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing Multiple Sclerosis

NCT01405820 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT01405820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01405820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Blinded, Parallel-Group, Phase 2 Study Exploring the Safety, Tolerability, and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing Multiple Sclerosis
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2011
Completion date
October 31, 2014
Enrollment
290 (actual)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing-remitting multiple sclerosis